Search Results | MSF Science Portal

Journal Article

|

Research

Van Heerden JK, Zhao Y, Keene CM, Griesel R, Omar Z, et al.

2025-04-30 • South African Journal of HIV Medicine

BACKGROUND

Dol...

Journal Article

|

Research

Huerga H, Gouillou M, Ohler L, Taremwa IM, Akinyi M, et al.

2025-04-23 • PLOS Global Public Health

People living with HIV (PLHIV) have an increased risk of tuberculosis (TB) and severe COVID-19. TB and COVI...

Journal Article

|

Research

Bulti AB, Dumicho AY, Shigayeva A, Van Cutsem G, Steele SJ, et al.

2025-04-23 • Scientific Reports

Tuberculosis (TB) among hospitalized patients is underdiagnosed. This study assessed systematic TB-screenin...

Journal Article

|

Research

Sweeney S, Laurence YV, Berry C, Singh MP, Dodd M, et al.

2025-02-01 • Lancet Global Health

BACKGROUND

New 6-month rifampicin-resistant tuberculosis treatment regimens containing bedaquiline, pretomanid, and linezolid (BPaL) with or without moxifloxaci...

Journal Article

|

Research

Guglielmetti L, Khan U, Velásquez GE, Gouillou M, Abubakirov A, et al.

2025-01-29 • New England Journal of Medicine

BACKGROUND

For decades, poor treatment options and low-quality evidence plagued care for patients with rifampin-resistant tuberculosis. The advent of new drugs ...

Journal Article

|

Research

Mukumbang FC, Ndlovu S, Adebiyi BO

2024-11-12 • BMC Public Health

INTRODUCTION

Migrant populations (asylum seekers, permit holders, refugees, and undocumented migrants) living in South Africa face various individual, social, a...

Journal Article

|

Research

Chihana M, Conan N, Ohler L, Huerga H, Wanjala S, et al.

2024-06-17 • Journal of the International Association of Providers of AIDS Care

BACKGROUND
The burden of advanced HIV disease remains a significant concern in sub-Saharan Africa. In 2015, the World Health Organization released recommendations to treat all people...

Journal Article

|

Research

Motta I, Cusinato M, Ludman AJ, Lachenal N, Dodd M, et al.

2024-06-06 • Antimicrobial Agents and Chemotherapy

Regimens for the treatment of rifampicin-resistant tuberculosis currently rely on the use of QT-prolonging agents. Using data from the randomized controlled trial, TB-PRACTECAL, we inves...

Conference Material

|

Slide Presentation

Guglielmetti L, Khan U, Velasquez GE, Gouillou M, Lachenal N, et al.

2024-05-16 • MSF Scientific Day International 2024

Conference Material

|

Video

Guglielmetti L

2024-05-16 • MSF Scientific Day International 2024

Conference Material

|

Slide Presentation

Gotham D, Martin M, Barber M, Kazounis E, Batts C, et al.

2024-05-16 • MSF Scientific Day International 2024

Conference Material

|

Abstract

Guglielmetti L, Khan U, Velasquez GE, Gouillou M, Lachenal N, et al.

2024-05-16 • MSF Scientific Day International 2024

INTRODUCTION
Tuberculosis (TB) is a major public health challenge encountered across many Médecins Sans Frontières (MSF) fields. Management of drug-resistant TB is an operational pri...

Journal Article

|

Review

Monk EJM, Jones TPW, Bongomin F, Kibone W, Nsubuga Y, et al.

2024-04-16 • PLOS Global Public Health

Antimicrobial resistance (AMR) is a major global threat and AMR-attributable mortality is particularly high in Central, Eastern, Southern and Western Africa. The burden of clinically inf...

Journal Article

|

Research

Arendse KD, Walker C, Pfaff C, Lebelo K, Cassidy T, et al.

2024-03-27 • Scientific Reports

Psychosocial challenges impact patients’ ability to remain on antiretroviral therapy lifelong, magnified by disorganized health-systems and healthcare worker (HCW) attitudes. To address ...

Journal Article

|

Review

Hasan T, Medcalf E, Nyang'wa BT, Egizi E, Berry C, et al.

2024-03-20 • Clinical Infectious Diseases

BACKGROUND
Effectiveness, safety, tolerability, and adherence are critical considerations in shifting to shorter tuberculosis (TB) regimens. Novel 6-month oral regimens that include ...

Journal Article

|

Pre-Print

Bulti AB, Dumicho AY, Shigayeva A, van Cutsem G, Steele SJ, et al.

2024-03-08 • Scientific Reports

BACKGROUND
Tuberculosis (TB) among hospitalized patients is underdiagnosed. This study assessed systematic TB-screening, followed by an enhanced TB-diagnostic package for hospitaliz...

Journal Article

|

Research

Shephard M, Matthews S, Kularatne R, Andrewartha K, Blondeel K, et al.

2024-03-04 • BMC Infectious Diseases

BACKGROUND
In 2018, the World Health Organization commenced a multi-country validation study of the Cepheid GeneXpert for a range of molecular-based point-of-care (POC) tests in prim...

Journal Article

|

Research

van Heerden JK, Meintjes G, Barr D, Zhao Y, Griesel R, et al.

2024-03-01 • Journal of Acquired Immune Deficiency Syndromes (JAIDS)

BACKGROUND
Tenofovir diphosphate (TFV-DP) concentration in dried blood spots is a marker of long-term adherence. We investigated the relationship between TFV-DP concentrations and vi...

Journal Article

|

Research

Nyang'wa BT, Berry C, Kazounis E, Motta I, Parpieva N, et al.

2024-02-01 • Lancet Respiratory Medicine

BACKGROUND
Around 500,000 people worldwide develop rifampicin-resistant tuberculosis each year. The proportion of successful treatment outcomes remains low and new treatments are nee...

Journal Article

|

Research

Guglielmetti L, Khan U, Velasquez GE, Gouillou M, Abubakirov A, et al.

2024-01-29 • medRxiv

BACKGROUND

Aft...

Science Portal

Longer-term virologic outcomes on tenofovir-lamivudine-dolutegravir in second-line ART

COVID-19, tuberculosis, and HIV triad: a prospective observational study in ambulatory patients in Kenya, Uganda, and South Africa

Enhancing tuberculosis (TB) case detection among hospitalized patients through lay health worker led screening: a before-and-after study in KwaZulu-Natal, South Africa

24-week, all-oral regimens for pulmonary rifampicin-resistant tuberculosis in TB-PRACTECAL trial sites: an economic evaluation

Oral regimens for rifampin-resistant, fluoroquinolone-susceptible tuberculosis

Experiences and perceptions of migrant populations in South Africa on COVID-19 immunization: an interpretative phenomenological analysis

Changes over time in the proportion of advanced HIV disease in two high HIV prevalence settings in Ndhiwa (Kenya) and Eshowe (South Africa)

How much should we still worry about QTc prolongation in rifampicin-resistant tuberculosis? ECG findings from TB-PRACTECAL clinical trial

Improving treatment of multidrug-resistant tuberculosis: Results of the endTB randomised clinical trial

Improving treatment of multidrug-resistant tuberculosis: Results of the endTB randomised clinical trial

Application of the Médecins Sans Frontières clinical trial transparency policy: cost analysis of TB-PRACTECAL, a multicentre phase 2–3 trial in drug-resistant tuberculosis

Improving treatment of multidrug-resistant tuberculosis: Results of the endTB randomised clinical trial

Antimicrobial resistance in bacterial wound, skin, soft tissue and surgical site infections in Central, Eastern, Southern and Western Africa: A systematic review and meta-analysis

Supporting re-engagement with HIV services after treatment interruption in South Africa: a mixed method program evaluation of MSF’s Welcome Service

The safety and tolerability of linezolid in novel short-course regimens containing bedaquiline, pretomanid, and linezolid to treat rifampicin-resistant tuberculosis: An individual patient data meta-analysis

Enhancing tuberculosis (TB) diagnosis among hospitalized patients in KwaZulu-Natal, South Africa: a before-and-after study of a lay health worker-driven intervention

Independent clinic-based evaluation of point-of-care testing for the screening of Chlamydia trachomatis, Neisseria gonorrhoea and Trichomonas vaginalis in women-at-risk in Australia, Guatemala, Morocco, and South Africa

Relationship between tenofovir diphosphate concentrations in dried blood spots and virological outcomes after initiating tenofovir-lamivudine-dolutegravir as first-line or second-line antiretroviral therapy

Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial

Nine-month, all-oral regimens for rifampin-resistant tuberculosis